Last reviewed · How we verify

NCT04411615

Effect of Re-esterified Triglyceride (rTG) Form Omega-3 Supplements on Dry Eye Following Cataract Surgery

Status unknown NA Last updated 2 June 2020
What this trial tests

NA trial testing Omega 3 in Dry Eye in 30 participants. Status unknown.

Timeline
1 July 2020
Primary endpoint
1 August 2020
28 February 2021

Quick facts

Lead sponsorSamsung Medical Center
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment30
Start date1 July 2020
Primary completion1 August 2020
Estimated completion28 February 2021

Drugs / interventions tested

Conditions studied

Sponsor

Samsung Medical Center

Who can join

Eligibility, any sex, with Dry Eye. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the clinical outcomes of the systemic re-esterified triglyceride (rTG) form of omega-3 fatty acids in patients with dry eye symptoms after cataract surgery

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Effects of the re-esterified triglyceride (rTG) form of omega-3 supplements on dry eye following cataract surgery.
    Park J, Yoo YS, Shin E, Han G, et al · · 2021 · cited 13× · PMID 32917627 · DOI 10.1136/bjophthalmol-2020-317164

Verify or expand the search:

Other trials of Omega 3

Trials testing the same drug.

Other recruiting trials for Dry Eye

Currently open trials in the same condition.

Other Samsung Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04411615.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing